RecruitingPhase 2NCT04966663

Using ctDNA to Determine Therapies for Lung Cancer

From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection

Sponsor

University Health Network, Toronto

Enrollment

66 participants

Start Date

Mar 28, 2022

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer Circulating Tumor DNA Complete Surgical Resection

Summary

This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses a liquid biopsy blood test (called ctDNA) to detect tiny traces of cancer DNA in the blood after lung cancer surgery. It aims to guide whether additional treatment is needed based on whether the test is positive or negative. **You may be eligible if...** - You are 18 years or older and weigh at least 35 kg - You have had complete surgical removal of early-stage non-small cell lung cancer (NSCLC, stage T1–T2N0M0 or T3/T4 multifocal) - Your ctDNA blood test was detectable before or after surgery - You have a life expectancy of at least 24 months - You are in good physical condition (ECOG status 0 or 1) - You have not previously received chemotherapy or radiation for this cancer **You may NOT be eligible if...** - Your ctDNA test is undetectable - You have received prior treatment for this lung cancer - You have had an incomplete surgical resection - Your general health is too poor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.